3,4-epoxy-3,4-dihydro-2H-1-benzopyran-6-carbonitrile | 148039-43-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3,4-epoxy-3,4-dihydro-2H-1-benzopyran-6-carbonitrile
• 英文别名: 6-cyano-3,4-dihydro-epoxy-2H-benzo[b]pyran；2,7b-dihydro-1aH-oxireno[2,3-c]chromene-6-carbonitrile
• CAS: 148039-43-4
• 化学式: C₁₀H₇NO₂
• 分子量: 173.171
• InChiKey: AMOZIKYBQAUOEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  45.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,4-epoxy-3,4-dihydro-2H-1-benzopyran-6-carbonitrile 在 potassium tert-butylate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 19.0h， 生成 trans-6-cyano-3,4-dihydro-4-(2-oxopyrrolidin-1-yl)-2H-1-benzopyran-3-yl methanesulphonate
  参考文献：
  名称：

  Buckle, Derek R.; Eggleston, Drake S.; Houge-Frydrych, Catherina S. V., Journal of the Chemical Society. Perkin transactions I, 1991, p. 2763 - 2772

  摘要：

  DOI：
• 作为产物：
  描述：

  3-(4-氰基苯氧基)丙酸 在 三氯化铝 、 钾硼氢 、 草酰氯 、 对甲苯磺酸 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 119.5h， 生成 3,4-epoxy-3,4-dihydro-2H-1-benzopyran-6-carbonitrile
  参考文献：
  名称：

  Buckle, Derek R.; Eggleston, Drake S.; Houge-Frydrych, Catherina S. V., Journal of the Chemical Society. Perkin transactions I, 1991, p. 2763 - 2772

  摘要：

  DOI：

文献信息

• Anti-hypertensive chromanol derivatives
  申请人：Beecham Group p.l.c.

  公开号：US04575511A1

  公开（公告）日：1986-03-11

  Compounds of formula (I): ##STR1## wherein: either one of R.sub.1 and R.sub.2 is hydrogen and the other is selected from the class of C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylcarbonyloxy, C.sub.1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C.sub.1-6 alkylsulphinyl, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkoxysulphinyl, C.sub.1-6 alkoxysulphonyl, C.sub.1-6 alkylcarbonylamino, C.sub.1-6 alkoxycarbonylamino, C.sub.1-6 alkyl-thiocarbonyl, C.sub.1-6 alkoxy-thiocarbonyl, C.sub.1-6 alkyl-thiocarbonyloxy, C.sub.1-6 alkyl-thiolmethyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C.sub.1-6 alkyl groups, or C.sub.1-6 alkoxysulphinylamino, C.sub.1-6 alkoxysulphonylamino C.sub.1-6 alkoxysulphinylamino or C.sub.1-6 alkoxysulphonylamino or ethylenyl terminally substituted by C.sub.1-6 alkylcarbonyl, nitro or cyano, or one of R.sub.1 and R.sub.2 is nitro, cyano or C.sub.1-3 alkylcarbonyl and the other is methoxy or amino optionally substituted by one or two C.sub.1-6 alkyl groups or by C.sub.2-7 alkanoyl; one of R.sub.3 and R.sub.4 is hydrogen or C.sub.1-4 alkyl and the other is C.sub.1-4 alkyl or R.sub.3 and R.sub.4 together are C.sub.2-5 polymethylene; either R.sub.5 is hydrogen, hydroxy, C.sub.1-6 alkoxy or C.sub.1-7 acyloxy and R.sub.6 is hydrogen or R.sub.5 and R.sub.6 together are a bond; R.sub.7 is selected from the class consisting of C.sub.1-6 alkyl substituted by amino optionally substituted by one or two C.sub.1-6 alkyl groups which may be the same or different; amino optionally substituted by a C.sub.1-6 alkyl or C.sub.1-6 alkenyl group or a C.sub.1-6 alkanoyl group optionally substituted by up to three halo atoms or by a phenyl group optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen; or C.sub.1-6 alkoxy, or phenoxy optionally substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen; or, when X is oxygen, R.sub.7 is further selected from the class of carboxy, C.sub.1-6 alkoxycarbonyl, or aminocarbonyl optionally substituted by one or two C.sub.1-6 alkyl groups which may be the same or different; R.sub.8 is hydrogen or C.sub.1-6 alkyl; and X is oxygen or sulphur; the R.sub.8 --N--CX--R.sub.7 group being trans to the R.sub.5 group when R.sub.5 and R.sub.6 together are not a bond; or when the compound of formula (I) contains a salifiable group, pharmaceutically acceptable salts thereof, having pharmacological activity, a process for preparing them, pharmaceutical compositions containing them, and their use in the treatment of mammals.

  式(I)的化合物：其中：R.sub.1和R.sub.2中的任一个是氢，另一个选自C.sub.1-6烷基羰基，C.sub.1-6烷氧羰基，C.sub.1-6烷基羰氧基，C.sub.1-6烷基羟甲基，硝基，氰基，氯基，三氟甲基，C.sub.1-6烷基砜基，C.sub.1-6烷基磺酰基，C.sub.1-6烷氧基砜基，C.sub.1-6烷氧基磺酰基，C.sub.1-6烷基羰基氨基，C.sub.1-6烷氧羰基氨基，C.sub.1-6烷基硫代羰基，C.sub.1-6烷氧基硫代羰基，C.sub.1-6烷基硫代羰氧基，C.sub.1-6烷基硫代硫醇甲基，甲酰基或氨基砜基，氨基磺酰基或氨基羰基，氨基基团可选择地被一个或两个C.sub.1-6烷基取代，或C.sub.1-6烷氧基砜基氨基，C.sub.1-6烷氧基磺酰基氨基，C.sub.1-6烷氧基砜基氨基或C.sub.1-6烷氧基磺酰基氨基，或末端被C.sub.1-6烷基羰基，硝基或氰基取代的乙烯基；R.sub.1和R.sub.2中的一个是硝基，氰基或C.sub.1-3烷基羰基，另一个是甲氧基或氨基，可选择地被一个或两个C.sub.1-6烷基或C.sub.2-7烷酰基取代；R.sub.3和R.sub.4中的一个是氢或C.sub.1-4烷基，另一个是C.sub.1-4烷基或R.sub.3和R.sub.4一起是C.sub.2-5聚亚甲基；R.sub.5是氢，羟基，C.sub.1-6烷氧基或C.sub.1-7酰氧基，R.sub.6是氢或R.sub.5和R.sub.6一起是键合；R.sub.7选自经氨基取代的C.sub.1-6烷基，可选择地被一个或两个相同或不同的C.sub.1-6烷基取代；氨基，可选择地被C.sub.1-6烷基或C.sub.1-6烯基取代或可选择地被高达三个卤原子取代或被可选择地被C.sub.1-6烷基，C.sub.1-6烷氧基或卤原子取代的苯基取代；或C.sub.1-6烷氧基，或可选择地被C.sub.1-6烷基，C.sub.1-6烷氧基或卤原子取代的苯氧基；或当X为氧时，R.sub.7进一步选自羧基，C.sub.1-6烷氧羰基，或氨基羰基，可选择地被一个或两个相同或不同的C.sub.1-6烷基取代；R.sub.8是氢或C.sub.1-6烷基；X是氧或硫；当R.sub.5和R.sub.6一起不是键合时，R.sub.8--N--CX--R.sub.7基与R.sub.5基是反式的；或当式(I)的化合物含有可盐化基团时，其药理活性的药用盐，制备它们的方法，含有它们的药物组合物，以及它们在治疗哺乳动物中的用途。
• Chroman and chromene derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0126367A1

  公开（公告）日：1984-11-28

  Compounds of formula (I): wherein: either one of R1 and R2 is hydrogen and the other is selected from the class of C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyloxy, C1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C1-6 alkylsulphinyl, C1-6 alkylsulphonyl, C1-6 alkoxysulphinyl, C1-6 alkoxysulphonyl, C1-6 alkylcarbonylamino, C1-6 alkoxycarbonylamino, C1-6 alkyl-thiocarbonyl, C1-6 alkoxy-thiocarbonyl, C1-6 alkyl-thiocarbonyloxy, C1-6 alkyl-thiomethyl, formyl or aminosulphinyl, aminosulphonyl or aminocarbonyl, the amino moiety being optionally substituted by one or two C1-6 alkyl groups, or C1-6 alkylsulphinylamino, C1-6 alkylsulphonylamino, C1-6 alkoxysulphinylamino or C1-6 alkoxysulphonylamino or ethylenyl terminally substituted by Cl-6 alkylcarbonyl, nitro or cyano, or one of R1 and R2 is nitro, cyano or C1-3 alkylcarbonyl and the other is methoxy or amino optionally substituted by one or two C1-6 alkyl groups or by C2-7 alkanoyl; one of R3 and R4 is hydrogen or Cl-4 alkyl and the other is Cl-4 alkyl or R3 and R4 together are C2-5 polymethylene; either R5 is hydrogen, hydroxy, C1-6 alkoxy or C1-7 acyloxy and R6 is hydrogen or R5 and R6 together are a bond; R7 is selected from the class consisting of C1-6 alkyl substituted by amino optionally substituted by one or two C1-6 alkyl groups which may be the same or different; amino optionally substituted by a C1-6 alkyl or C1-6 alkenyl group or a C5-8 cycloalkyl group or by a phenyl group optionally substituted by C1-6 alkyl, Cl-6 alkoxy or halogen; or C1-6 alkoxy, or phenoxy optionally substituted by C1-6 alkyl, C1-6 alkoxy or halogen; or, when X is oxygen, R7 is selected from the class of carboxy, C1-6 alkoxycarbonyl, or aminocarbonyl optionally substituted by one or two C1-6 alkyl groups which may be the same or different; R8 is hydrogen or C1-6 alkyl; and X is oxygen or sulphur; The R8-N-CX-R7 group being trans to the R5 group when R5 and R6 together are not a bond; or when the compound of formula (I) contains a salifiable group, pharmaceutically acceptable salts thereof, having pharmacological activity, a process for preparing them, pharmaceutical compositions containing them, and their use in the treatment of mammals.

  式(I)化合物： 其中 R1 和 R2 中的任一个为氢，另一个选自 C1-6 烷基羰基、C1-6 烷氧基羰基、C1-6 烷基羰氧基、C1-6 烷基羟甲基、硝基、氰基、氯基、三氟甲基、C1-6 烷基亚磺酰基、C1-6 烷基磺酰基、C1-6 烷氧基磺酰基、C1-6 烷基羰基、C1-6 烷氧基磺酰基、C1-6 烷基羰基C1-6烷基磺酰基、C1-6烷氧基磺酰基、C1-6烷氧基磺酰基、C1-6烷基羰基氨基、C1-6烷氧基羰基氨基、C1-6烷基硫代羰基、C1-6烷氧基硫代羰基、C1-6烷基硫代羰氧基、C1-6烷基硫甲基、甲酰基或氨基磺酰基、氨基磺酰基或氨基羰基，氨基可选择被一个或两个 C1-6 烷基取代，或被 C1-6 烷基亚磺酰氨基、C1-6 烷基磺酰基氨基、C1-6 烷氧基亚磺酰氨基或 C1-6 烷氧基磺酰基氨基或被 Cl-6 烷基羰基最终取代的乙烯基、R1和R2中的一个是硝基、氰基或C1-3烷基羰基，另一个是甲氧基或被一个或两个C1-6烷基或C2-7烷酰基任选取代的氨基；R3 和 R4 中的一个是氢或 Cl-4 烷基，另一个是 Cl-4 烷基，或 R3 和 R4 合在一起是 C2-5 聚亚甲基；R5 是氢、羟基、C1-6 烷氧基或 C1-7 乙酰氧基，R6 是氢，或 R5 和 R6 合在一起是键；R7 选自由氨基任选取代的 C1-6 烷基组成的类别，氨基任选被一个或两个 C1-6 烷基取代，这两个 C1-6 烷基可以相同或不同；被 C1-6 烷基或 C1-6 烯基或 C5-8 环烷基或被 C1-6 烷基、Cl-6 烷氧基或卤素任选取代的苯基任选取代的氨基；或被 C1-6 烷基、C1-6 烷氧基或卤素任选取代的 C1-6 烷氧基或苯氧基；或当 X 为氧时，R7 选自被一个或两个可能相同或不同的 C1-6 烷基任选取代的羧基、C1-6 烷氧基羰基或氨基羰基； R8 是氢或 C1-6 烷基；以及 X 是氧或硫； 当 R5 和 R6 合在一起不是键时，R8-N-CX-R7 基团反式为 R5 基团； 或当式(I)化合物含有可盐基团时，具有药理活性的其药学上可接受的盐、制备它们的工艺、含有它们的药物组合物，以及它们在治疗哺乳动物中的用途。
• US4575511A
  申请人：——

  公开号：US4575511A

  公开（公告）日：1986-03-11
• Buckle, Derek R.; Eggleston, Drake S.; Houge-Frydrych, Catherina S. V., Journal of the Chemical Society. Perkin transactions I, 1991, p. 2763 - 2772
  作者：Buckle, Derek R.、Eggleston, Drake S.、Houge-Frydrych, Catherina S. V.、Pinto, Ivan L.、Readshaw, Simon A.、et al.

  DOI：——

  日期：——